NooCube Reviews: Announces U.S. Availability of Nootropic for Brain Productivity Supplement

Updated caffeine-free formulation contains 12 disclosed ingredients, including Bacopa Monnieri, Panax Ginseng, choline, L-Theanine and a carotenoid blend

GLASGOW, Scotland, September 15, 2026 — NooCube has announced the current U.S. availability of its Brain Productivity v3.0 dietary supplement, a caffeine-free nootropic formulation containing 12 disclosed nutritional, botanical and related ingredients.

The current v3.0 formula reflects several changes from earlier versions of NooCube. According to published product information, Oat Straw Extract has been replaced with Panax Ginseng concentrate, while the previously used Alpha GPC has been replaced with a different choline source. Biotin has been updated to D-Biotin, and the formulation uses vegetable-derived magnesium stearate.

NooCube describes the changes as part of an update that makes the current formulation suitable for vegetarians while maintaining the product’s caffeine-free positioning. The current formula includes Bacopa Monnieri, Panax Ginseng, choline, L-Theanine, L-Tyrosine, Cat’s Claw extract, resveratrol, pterostilbene, carotenoids and B vitamins.

The product is marketed toward adults interested in incorporating nutritional and botanical ingredients associated with cognitive wellness into their daily routine. NooCube is a dietary supplement rather than a prescription medication, and research involving its individual ingredients should not automatically be interpreted as clinical evidence regarding the complete multi-ingredient product.

“Brain Productivity v3.0 represents the current evolution of the NooCube formula, including updates to several ingredients while maintaining its caffeine-free positioning,” said Kevin Shaw, Media Relations Representative for NooCube. “We want consumers and media outlets to have access to current formulation information and appropriate scientific context without overstating what ingredient-level research can establish.” 

Current v3.0 Formula Updates Earlier Ingredient Profile

One of the key features of Brain Productivity v3.0 is the distinction between the current formulation and earlier versions of NooCube. Current product information states that the previous Alpha GPC ingredient has been replaced with a different choline source, while Oat Straw Extract has been replaced with Panax Ginseng concentrate.

The formula also uses D-Biotin and vegetable-derived magnesium stearate. These differences are relevant because older third-party reviews and product descriptions may continue to reference ingredients associated with previous NooCube formulations.

Consumers evaluating the product should therefore rely on the current Supplement Facts panel and current manufacturer information rather than assuming that older ingredient lists remain accurate.

The current formulation contains 12 principal dietary ingredients rather than the 13 ingredients described in some previous product materials.

Bacopa Monnieri Remains a Botanical Component

Bacopa Monnieri is one of the primary botanical ingredients included in the current formulation. The product identifies a concentrated Bacopa Monnieri extract standardized for bacosides.

Bacopa has a long history of traditional use and has also been examined in modern research involving areas such as memory, information processing and other measures of cognitive performance. The interpretation of this research requires context.

Studies involving Bacopa may use specific standardized extracts, controlled dosages and defined treatment periods. Outcomes can also differ according to participant age, health status and study design.

Research involving Bacopa Monnieri as a standalone ingredient therefore provides scientific context for its inclusion in a cognitive-wellness formulation but does not establish that the complete NooCube product produces the same outcomes. This distinction is especially important with multi-ingredient dietary supplements, where several botanicals, nutrients and other compounds are combined within one formula.

Panax Ginseng Replaces Oat Straw Extract

Panax Ginseng is one of the notable changes in NooCube Brain Productivity v3.0. Current company information states that Oat Straw Extract used in an earlier version of the formulation has been replaced with concentrated Panax Ginseng.

Panax Ginseng has a long history of traditional use and has been examined in scientific research involving areas such as fatigue, stress and cognitive performance. Human studies involving ginseng vary substantially in preparation, concentration, dosage and duration.

The presence of Panax Ginseng in NooCube should therefore be understood as a formulation component rather than evidence that the finished product has demonstrated every outcome associated with independent ginseng research.

Traditional use also should not be treated as equivalent to modern clinical evidence. Historical use can explain why a botanical attracts research interest, but conclusions concerning human health outcomes depend on the quality and type of scientific evidence available.

Current Formula Includes a Choline Source

Choline is an essential nutrient involved in several normal physiological functions and is used by the body in the synthesis of acetylcholine, a neurotransmitter involved in nervous-system signaling. Earlier versions of NooCube contained Alpha GPC. The current formula instead uses another choline source.

That distinction is important when evaluating scientific literature. Research involving Alpha GPC should not automatically be used to support claims concerning a different form of choline simply because both provide choline.

Different ingredient forms can vary in composition, absorption, dosing and research history. The presence of choline within the NooCube formulation therefore establishes the ingredient’s inclusion but does not by itself demonstrate that the finished supplement improves memory, concentration, mood or another specific cognitive outcome.

L-Theanine and L-Tyrosine Add Amino-Acid Components

L-Theanine is an amino acid naturally associated with tea and has been studied in research involving relaxation, attention and responses to stress. L-Tyrosine is an amino acid involved in the production of several compounds used by the body, including catecholamine neurotransmitters.

Research concerning both ingredients varies by dose, participant population, study duration and experimental conditions. Accordingly, studies involving L-Theanine or L-Tyrosine independently should not be interpreted as clinical trials of NooCube.

The current NooCube formula does not contain caffeine, although L-Theanine has sometimes been studied together with caffeine in unrelated research. That distinction helps avoid implying that results from caffeine-and-theanine studies apply directly to a caffeine-free supplement.

Carotenoids Add Another Nutritional Category

Carotenoids are naturally occurring pigments found in foods including vegetables and have been extensively researched in areas such as visual function. Some research has also examined relationships between carotenoid status and cognitive measures.

The inclusion of carotenoids adds another nutritional category to the NooCube formula beyond botanical extracts, amino-acid-related ingredients and B vitamins. As with the other ingredients, findings involving an individual carotenoid preparation should not automatically be generalized to the complete NooCube formulation.

Ingredient-level studies can help explain why certain compounds attract scientific interest, but they are not equivalent to clinical evidence concerning a finished multi-ingredient product.

Resveratrol and Pterostilbene Are Included as Plant-Derived Compounds

Both are naturally occurring plant compounds that have been studied across a range of nutritional and biomedical research areas. Resveratrol has attracted particular interest in research involving cellular and metabolic processes.

Pterostilbene is chemically related to resveratrol and has also been investigated experimentally. The strength of evidence differs according to the specific outcome being evaluated.

Laboratory findings, animal studies and mechanistic research should not be presented as evidence that a commercial dietary supplement will necessarily produce the same effects in humans. Their inclusion in NooCube establishes what is present in the formulation but does not establish a guaranteed or clinically proven cognitive effect for the finished product.

Cat’s Claw Research Requires Careful Interpretation

The plant has a history of traditional use and has been examined in laboratory and preclinical research. Some experimental research involving compounds derived from Cat’s Claw has investigated biological pathways relevant to neurological science. Those findings require careful interpretation.

Laboratory observations involving isolated plant compounds do not establish that consuming a commercial dietary supplement containing Cat’s Claw will prevent memory loss or treat neurological disease.

NooCube therefore should not be described as preventing or treating Alzheimer’s disease, dementia or another neurological condition based on research involving Cat’s Claw. Such claims would require substantially different evidence and regulatory treatment.

B Vitamins Provide a Micronutrient Component

The current formulation also includes Vitamin B1, D-Biotin and Vitamin B12. B vitamins participate in numerous normal metabolic processes. Vitamin B1, also called thiamine, contributes to normal cellular metabolism.

Biotin functions as a cofactor in several metabolic pathways. Vitamin B12 is involved in processes including normal red-blood-cell formation and nervous-system function.

These established physiological roles should not be confused with claims that supplementation necessarily improves cognitive performance in individuals who already obtain adequate amounts of these nutrients.

A nutrient can be essential for normal function without additional intake necessarily producing additional performance benefits.

Why Ingredient Research Is Different From Finished-Product Evidence

The ingredient profile of NooCube illustrates an important principle in dietary-supplement research: evidence about an individual ingredient is not automatically evidence about a complete commercial formulation.

Scientific studies can take many forms. Researchers may study compounds in cell cultures, evaluate ingredients in animal models, conduct observational human research or perform randomized controlled trials.

Each type of research answers a different scientific question. A controlled trial involving a standardized Bacopa extract, for example, does not demonstrate that a formula combining Bacopa with 11 other ingredients will necessarily produce the same outcome.

Similarly, research involving Panax Ginseng does not prove the efficacy of NooCube simply because the product contains ginseng. Research involving one form of choline also does not establish the effects of every other choline source.

Dosage, formulation, extraction methods, bioavailability, study duration and participant characteristics can all affect findings. Ingredient research can therefore provide useful scientific context without being presented as proof of finished-product efficacy.

FDA Rules Distinguish Supplement Claims From Disease Claims

Dietary supplements in the United States are regulated differently from prescription drugs. The U.S. Food and Drug Administration permits certain structure/function and general-well-being claims when applicable requirements are met, but such claims must be truthful and appropriately substantiated.

Dietary supplements cannot legally be marketed as products that diagnose, treat or cure diseases unless they meet the regulatory requirements applicable to drugs.

Dr. Cara Welch, Director of the FDA’s Office of Dietary Supplement Programs, has summarized the distinction by explaining that dietary supplements “are not permitted to make claims to diagnose, treat, or cure diseases.”

That distinction is relevant when discussing cognitive-wellness supplements. NooCube should therefore not be interpreted as a treatment for Alzheimer’s disease, dementia, attention disorders, depression, anxiety or another diagnosed neurological or psychiatric condition.

Persistent or worsening changes in memory, attention, mood or cognition can have many causes and may require evaluation by an appropriate healthcare professional.

Product Availability and Consumer Information

NooCube Brain Productivity v3.0 is currently marketed to U.S. consumers through the company’s official website. Consumers should verify current serving instructions, pricing, package configurations, shipping terms and availability directly through current company information because commercial details may change.

The physical product label and current Supplement Facts panel should remain the primary sources for ingredient quantities, serving directions and applicable warnings. People taking prescription medication, using other dietary supplements, managing an existing health condition, or who are pregnant or nursing should discuss supplementation with an appropriate healthcare professional.

Botanical ingredients and nutritional supplements may not be appropriate for every individual.

About NooCube

NooCube Brain Productivity is a caffeine-free dietary supplement containing a combination of botanical extracts, amino-acid-related ingredients, vitamins, carotenoids and other nutritional compounds.

The current Brain Productivity v3.0 formulation contains 12 disclosed ingredients and includes changes from earlier versions, including Panax Ginseng in place of Oat Straw Extract and a different choline source in place of Alpha GPC. Current company information identifies Wolfson Brands LIMITED as the supplier and manufacturer of NooCube.

Important Consumer Information

NooCube is a dietary supplement and is not a medication. Research concerning individual ingredients mentioned in this release relates to those ingredients studied independently and should not be interpreted as clinical evidence regarding the safety or effectiveness of the complete NooCube formulation.

Research involving an individual ingredient does not establish that NooCube will produce the same outcome.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Consumers experiencing persistent cognitive or neurological symptoms should seek appropriate medical evaluation rather than attempting to manage those symptoms solely with a dietary supplement. Individual experiences with dietary supplements may vary.

Media Contact

Kevin Shaw, Media Relations, NooCube

314 Battlefield Road, Glasgow, G42 9JD

Email: support@noocube.com
Website: NooCube.com